We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
In the latest close session, Eli Lilly (LLY - Free Report) was up +2.09% at $1,222.61. The stock outperformed the S&P 500, which registered a daily gain of 0.21%. On the other hand, the Dow registered a gain of 1.03%, and the technology-centric Nasdaq decreased by 0.22%.
The stock of drugmaker has fallen by 2.63% in the past month, lagging the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.
Market participants will be closely following the financial results of Eli Lilly in its upcoming release. The company plans to announce its earnings on August 5, 2026. In that report, analysts expect Eli Lilly to post earnings of $6.71 per share. This would mark year-over-year growth of 6.34%. In the meantime, our current consensus estimate forecasts the revenue to be $20.26 billion, indicating a 30.24% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $35.03 per share and revenue of $85.78 billion, which would represent changes of +44.69% and +31.61%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.17% lower. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 34.19. Its industry sports an average Forward P/E of 17.68, so one might conclude that Eli Lilly is trading at a premium comparatively.
Also, we should mention that LLY has a PEG ratio of 1.48. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.69 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 231, this industry ranks in the bottom 7% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
In the latest close session, Eli Lilly (LLY - Free Report) was up +2.09% at $1,222.61. The stock outperformed the S&P 500, which registered a daily gain of 0.21%. On the other hand, the Dow registered a gain of 1.03%, and the technology-centric Nasdaq decreased by 0.22%.
The stock of drugmaker has fallen by 2.63% in the past month, lagging the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.
Market participants will be closely following the financial results of Eli Lilly in its upcoming release. The company plans to announce its earnings on August 5, 2026. In that report, analysts expect Eli Lilly to post earnings of $6.71 per share. This would mark year-over-year growth of 6.34%. In the meantime, our current consensus estimate forecasts the revenue to be $20.26 billion, indicating a 30.24% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $35.03 per share and revenue of $85.78 billion, which would represent changes of +44.69% and +31.61%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.17% lower. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 34.19. Its industry sports an average Forward P/E of 17.68, so one might conclude that Eli Lilly is trading at a premium comparatively.
Also, we should mention that LLY has a PEG ratio of 1.48. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.69 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 231, this industry ranks in the bottom 7% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.